Damora Therapeutics, Inc.DMRA
Price (close)
$20.66
Market cap
$1.3B
P/E
—
Revenue (TTM)
—
Net income
-$262.8M
Dividend yield
—
1-year total return
364.3%
Net margin
—
Revenue growth
—
Debt / equity
—
What Damora Therapeutics, Inc. does.
No business description on file yet.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net income | -$34.8M | -$51.8M | -$61.6M | -$38.3M | -$21.4M | -$209.8M |
| Free cash flow | — | -$52.5M | -$43.1M | — | — | — |
More on DMRA.
- Damora Therapeutics, Inc. summary
- Damora Therapeutics, Inc. financial statements
- Damora Therapeutics, Inc. key metrics
- Damora Therapeutics, Inc. health scores and style box
- Damora Therapeutics, Inc. earnings
- Damora Therapeutics, Inc. dividends
- Damora Therapeutics, Inc. valuation
- Damora Therapeutics, Inc. ownership and insiders
- Damora Therapeutics, Inc. peers
Figures from Damora Therapeutics, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.